Abstract:Anaplastic lymphoma kinase rearranged (ALK+) non–small-cell lung cancer demonstrates remarkable sensitivity to crizotinib.1Camidge DR Bang YJ Kwak EL et al.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012; 13: 1011-1019Abstract Full Text Full Text PDF PubMed Scopus (1064) Google Scholar Although other methods exist, the dominant method for determining ALK positivity uses the Abbott (Abbott Molecular, Des Plaines, IL) ALK break-apart fluorescent in situ hybridization (FISH) assay.2Weickhardt AJ Aisner DL Franklin WA Varella-Garcia M Doebele RC Camidge DR Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Cancer. 2013; 119: 1467-1477Crossref PubMed Scopus (66) Google Scholar The assay has clearly defined positivity criteria but borderline or atypical negative cases occur. Here we describe a case with an atypical negative FISH result that was later confirmed as ALK+ by both immunohistochemistry (IHC) and reverse transcription polymerase chain reaction (RT-PCR)and responded well to crizotinib. A 44-year-old Chinese man with a 7 pack-year smoking history was referred to Shanghai Pulmonary Hospital in February 2013 for a left upper lobe lung mass with multiple bilateral intrapulmonary metastases, left pleural effusion, and 2R/4R/10L/11L lymphadenopathy. Pleural fluid cytology revealed adenocarcinoma and Scorpion Amplification Refractory Mutation system (AmoyDx Co., Xiamen, China). showed no detectable epidermal growth factor receptor mutation. He commenced chemotherapy with gemcitabine and cisplatin. However, after a single cycle, his symptoms worsened and imaging confirmed progressive disease. A second opinion was requested from the University of Colorado and a computed tomography–guided biopsy of the left upper lobe lesion was performed to permit additional molecular testing. In the interim, the patient commenced pemetrexed and nedaplatin. Unfortunately, after two cycles his shortness of breath worsened, with evidence of further progression on his scans (Fig. 1A). Molecular testing on his repeat biopsy specimen revealed no mutations by SNaPshot multiplex PCR testing (Life Technologies, Carlsbad, CA). However, although technically negative, the ALK break-apart FISH test showed an atypical negative pattern. Specifically, 68% of cells demonstrated single copies of the 5′ ALK signal and numerous cells with doublets of the 5′ ALK signal combined with one 3′ ALK signal (Fig. 2A). Subsequently, confirmatory diagnostic assays demonstrated ALK protein expression by IHC using the D5F3 antibody (Cell Signaling Technology Inc., Danvers, MA; H score = 150; Fig. 2B) and the presence of an echinoderm microtubule-associated protein-like 4 (EML4)-ALK transcript (E13;A20) by RT-PCR (Fig. 2C). The patient then received crizotinib (250 mg twice daily) as third-line therapy in May 2013 with an impressive symptomatic improvement and CT response after 1 month of therapy (Fig. 1B). He remains on treatment with crizotinib with no evidence of progression as of September 2013. Isolated 5′ ALK signals have previously been reported, although, because the 5′ probe is not located in the kinase region of ALK, these are usually considered ALK negative by FISH.3Yoshida A Tsuta K Nitta H et al.Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas.J Thorac Oncol. 2011; 6: 1677-1686Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar,4Camidge DR Kono SA Flacco A et al.Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.Clin Cancer Res. 2010; 16: 5581-5590Crossref PubMed Scopus (297) Google Scholar Our patient showed multiple single copies of the 5′ ALK signal plus additional 5′ doublets combined with 3′ signals, suggesting the possibility of a complex rearrangement. ALK positivity was confirmed by both IHC and RT-PCR and the patient responded well to crizotinib. A complex rearrangement generating a different atypical negative FISH pattern (3′ doublets fused with 5′ signals) that also harbored a functional ALK fusion was recently described.5Peled N Palmer G Hirsch FR et al.Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.J Thorac Oncol. 2012; 7: e14-e16Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar When FISH is the initial diagnostic assay, consideration should be given to formally defining an atypical negative ALK FISH category for additional interrogation with alternative confirmatory assays.2Weickhardt AJ Aisner DL Franklin WA Varella-Garcia M Doebele RC Camidge DR Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.Cancer. 2013; 119: 1467-1477Crossref PubMed Scopus (66) Google Scholar

Comparison of ALK Detection by FISH, IHC and NGS to Predict Benefit from Crizotinib in Advanced Non-Small-cell Lung Cancer.

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer

A Survival Comparison Study of Chinese Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements with Crizotinib Treatment Detected by FISH, IHC, and RT-PCR.

Investigation on the Prognostic Impact of Concurrent Genomic Alterations in Crizotinib-Treated EML4-ALK-rearranged Advanced Non-Small Cell Lung Cancer Patients.

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy.

Feasibility of Cytological Specimens for ALK Fusion Detection in Patients with Advanced NSCLC Using the Method of RT-PCR.

Atypical Negative Alk Break-Apart Fish Harboring A Crizotinib-Responsive Alk Rearrangement in Non-Small-Cell Lung Cancer

Crizotinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Versus Chemotherapy As a First-Line Treatment

P1.01-006 Effect of EML-Alk Fusion Variant and Fusion Abundance on the Efficacy of Crizotinib in Non-Small Cell Lung Cancer

Anaplastic Lymphoma Kinase Variants and the Percentage of Alk-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced Nsclc

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib

Parallel Ventana Ihc And R.-Pcp Of Ack Status In Non-Small Cell Lung Cancer And Response To Crizotinib.

The Correlation Between Crizotinib Efficacy and Molecular Heterogeneity by Next-Generation Sequencing in Non-Small Cell Lung Cancer.

Landscape of Next Generation Sequencing in Screening Accurate Benefit Population for First Line Crizotinib in ALK Rearranged Advanced Non-Small Cell Lung Cancer

Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion

Responses to Crizotinib Therapy in Five Patients with Non-Small-cell Lung Cancer Who Tested FISH Negative and Ventana Immunohistochemistry Positive for ALK Fusions.

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer

P1.13-08 Distribution, Differences in Clinical Characteristics and Resistance Mechanism of ALK Variants in Chinese Lung Cancer Patients

P1.14-47 Ctdna NGS for Guiding Crizotinib Treatment in ALK-Rearranged Advanced NSCLC Patients (Pts)

IHC versus FISH versus NGS to detect ALK gene rearrangement in NSCLC: all questions answered?